Castro et al. examined 2019 men with prostate cancer (18 BRCA1 carriers, 61 BRCA2 carriers and 1940 noncarriers) with the aims of determining the independent prognostic value of BRCA1 and BRCA2 mutations on prostate cancer characteristics and survival29. This evidence concerns the gene BRCA2 and prostate cancer.